Does the media favor LPCN or HRTX?

In the previous week, Lipocine had 11 more articles in the media than Heron Therapeutics. MarketBeat recorded 13 mentions for Lipocine and 2 mentions for Heron Therapeutics. Lipocine's average media sentiment score of 0.64 beat Heron Therapeutics' score of 0.24 indicating that Lipocine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 3 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Heron Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ELOX or LPCN?

In the previous week, Lipocine had 10 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 13 mentions for Lipocine and 3 mentions for Eloxx Pharmaceuticals. Lipocine's average media sentiment score of 0.64 beat Eloxx Pharmaceuticals' score of 0.00 indicating that Lipocine is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eloxx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lipocine 3 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, LPCN or ATHE?

Lipocine has higher revenue and earnings than Alterity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lipocine $1.98M 7.16 -$9.63M -$1.79 N/A Alterity Therapeutics N/A N/A -$15.88M N/A N/A

Does the media favor LPCN or ATHE?

In the previous week, Lipocine had 7 more articles in the media than Alterity Therapeutics. MarketBeat recorded 13 mentions for Lipocine and 6 mentions for Alterity Therapeutics. Lipocine's average media sentiment score of 0.64 beat Alterity Therapeutics' score of 0.00 indicating that Lipocine is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 3 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate LPCN or ZYBT?

Lipocine currently has a consensus target price of $4.00, indicating a potential upside of 132.56%. Given Lipocine's stronger consensus rating and higher possible upside, research analysts clearly believe Lipocine is more favorable than Zhengye Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Zhengye Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, LPCN or ZYBT?

Lipocine has higher earnings, but lower revenue than Zhengye Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lipocine $1.98M 7.16 -$9.63M -$1.79 N/A Zhengye Biotechnology $116.36M 0.70 -$9.98M N/A N/A

Does the media prefer LPCN or ZYBT?

In the previous week, Lipocine had 7 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 13 mentions for Lipocine and 6 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.67 beat Lipocine's score of 0.64 indicating that Zhengye Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lipocine 3 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zhengye Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend LPCN or INCR?

Lipocine currently has a consensus target price of $4.00, suggesting a potential upside of 132.56%. Given Lipocine's stronger consensus rating and higher possible upside, equities analysts clearly believe Lipocine is more favorable than InterCure. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lipocine 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 InterCure 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, LPCN or INCR?

Lipocine has higher earnings, but lower revenue than InterCure. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lipocine $1.98M 7.16 -$9.63M -$1.79 N/A InterCure $78.47M 0.69 -$10.37M N/A N/A

Is LPCN or INCR more profitable?

InterCure has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. InterCure's return on equity of 0.00% beat Lipocine's return on equity. Company Net Margins Return on Equity Return on Assets Lipocine -755.39% -64.75% -57.62% InterCure N/A N/A N/A

Lipocine (LPCN) Competitors

$1.72 -0.21 (-10.88%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.74 +0.03 (+1.45%)

As of 10/9/2026 07:58 PM Eastern

Compare

LPCN vs. HRTX, ELOX, ATHE, ZYBT, and INCR

Should you buy Lipocine stock or one of its competitors? Lipocine's main competitors and comparable companies include Heron Therapeutics (HRTX), Eloxx Pharmaceuticals (ELOX), Alterity Therapeutics (ATHE), Zhengye Biotechnology (ZYBT), and InterCure (INCR). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Lipocine compare to Heron Therapeutics?

Lipocine (NASDAQ:LPCN) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends.

9.1% of Lipocine shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 4.7% of Lipocine shares are held by insiders. Comparatively, 6.1% of Heron Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Lipocine had 11 more articles in the media than Heron Therapeutics. MarketBeat recorded 13 mentions for Lipocine and 2 mentions for Heron Therapeutics. Lipocine's average media sentiment score of 0.64 beat Heron Therapeutics' score of 0.24 indicating that Lipocine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Heron Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lipocine has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market. Comparatively, Heron Therapeutics has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market.

Lipocine currently has a consensus price target of $4.00, indicating a potential upside of 132.56%. Heron Therapeutics has a consensus price target of $2.00, indicating a potential upside of 392.49%. Given Heron Therapeutics' higher probable upside, analysts plainly believe Heron Therapeutics is more favorable than Lipocine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Heron Therapeutics	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Heron Therapeutics has a net margin of -22.52% compared to Lipocine's net margin of -755.39%. Lipocine's return on equity of -64.75% beat Heron Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-755.39%	-64.75%	-57.62%
Heron Therapeutics	-22.52%	-293.02%	-10.00%

Lipocine has higher earnings, but lower revenue than Heron Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	7.16	-$9.63M	-$1.79	N/A
Heron Therapeutics	$151.18M	0.51	-$20.19M	-$0.19	N/A

Summary

Heron Therapeutics beats Lipocine on 8 of the 14 factors compared between the two stocks.

How does Lipocine compare to Eloxx Pharmaceuticals?

Eloxx Pharmaceuticals (NASDAQ:ELOX) and Lipocine (NASDAQ:LPCN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

In the previous week, Lipocine had 10 more articles in the media than Eloxx Pharmaceuticals. MarketBeat recorded 13 mentions for Lipocine and 3 mentions for Eloxx Pharmaceuticals. Lipocine's average media sentiment score of 0.64 beat Eloxx Pharmaceuticals' score of 0.00 indicating that Lipocine is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eloxx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lipocine	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by company insiders. Comparatively, 4.7% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Eloxx Pharmaceuticals has higher revenue and earnings than Lipocine. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eloxx Pharmaceuticals	$6.36M	8.73	-$5.99M	-$1.54	N/A
Lipocine	$1.98M	7.16	-$9.63M	-$1.79	N/A

Eloxx Pharmaceuticals has a beta of -1960.42, indicating that its share price is 196,142% less volatile than the broader market. Comparatively, Lipocine has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market.

Eloxx Pharmaceuticals currently has a consensus target price of $38.33, suggesting a potential upside of 178.99%. Lipocine has a consensus target price of $4.00, suggesting a potential upside of 132.56%. Given Eloxx Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts plainly believe Eloxx Pharmaceuticals is more favorable than Lipocine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eloxx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Lipocine	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Eloxx Pharmaceuticals has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Eloxx Pharmaceuticals' return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eloxx Pharmaceuticals	N/A	N/A	N/A
Lipocine	-755.39%	-64.75%	-57.62%

Summary

Eloxx Pharmaceuticals beats Lipocine on 12 of the 17 factors compared between the two stocks.

How does Lipocine compare to Alterity Therapeutics?

Lipocine (NASDAQ:LPCN) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, media sentiment, risk, institutional ownership, earnings, dividends and analyst recommendations.

Lipocine has higher revenue and earnings than Alterity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	7.16	-$9.63M	-$1.79	N/A
Alterity Therapeutics	N/A	N/A	-$15.88M	N/A	N/A

Lipocine presently has a consensus target price of $4.00, suggesting a potential upside of 132.56%. Alterity Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 220.51%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Alterity Therapeutics is more favorable than Lipocine.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Lipocine has a beta of 0.4, indicating that its stock price is 60% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

9.1% of Lipocine shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 4.7% of Lipocine shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Alterity Therapeutics has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Alterity Therapeutics' return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-755.39%	-64.75%	-57.62%
Alterity Therapeutics	N/A	N/A	N/A

In the previous week, Lipocine had 7 more articles in the media than Alterity Therapeutics. MarketBeat recorded 13 mentions for Lipocine and 6 mentions for Alterity Therapeutics. Lipocine's average media sentiment score of 0.64 beat Alterity Therapeutics' score of 0.00 indicating that Lipocine is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Alterity Therapeutics beats Lipocine on 7 of the 13 factors compared between the two stocks.

How does Lipocine compare to Zhengye Biotechnology?

Lipocine (NASDAQ:LPCN) and Zhengye Biotechnology (NASDAQ:ZYBT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment, valuation and dividends.

In the previous week, Lipocine had 7 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 13 mentions for Lipocine and 6 mentions for Zhengye Biotechnology. Zhengye Biotechnology's average media sentiment score of 0.67 beat Lipocine's score of 0.64 indicating that Zhengye Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	3 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Zhengye Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lipocine currently has a consensus target price of $4.00, indicating a potential upside of 132.56%. Given Lipocine's stronger consensus rating and higher possible upside, research analysts clearly believe Lipocine is more favorable than Zhengye Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Zhengye Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lipocine has higher earnings, but lower revenue than Zhengye Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	7.16	-$9.63M	-$1.79	N/A
Zhengye Biotechnology	$116.36M	0.70	-$9.98M	N/A	N/A

Lipocine has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, Zhengye Biotechnology has a beta of -2.31, indicating that its share price is 331% less volatile than the broader market.

9.1% of Lipocine shares are owned by institutional investors. 4.7% of Lipocine shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Zhengye Biotechnology has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. Zhengye Biotechnology's return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-755.39%	-64.75%	-57.62%
Zhengye Biotechnology	N/A	N/A	N/A

Summary

Lipocine beats Zhengye Biotechnology on 9 of the 14 factors compared between the two stocks.

How does Lipocine compare to InterCure?

Lipocine (NASDAQ:LPCN) and InterCure (NASDAQ:INCR) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends and valuation.

In the previous week, Lipocine had 12 more articles in the media than InterCure. MarketBeat recorded 13 mentions for Lipocine and 1 mentions for InterCure. Lipocine's average media sentiment score of 0.64 beat InterCure's score of 0.00 indicating that Lipocine is being referred to more favorably in the media.

Company	Overall Sentiment
Lipocine	Positive
InterCure	Neutral

Lipocine currently has a consensus target price of $4.00, suggesting a potential upside of 132.56%. Given Lipocine's stronger consensus rating and higher possible upside, equities analysts clearly believe Lipocine is more favorable than InterCure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
InterCure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lipocine has a beta of 0.4, indicating that its share price is 60% less volatile than the broader market. Comparatively, InterCure has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market.

InterCure has a net margin of 0.00% compared to Lipocine's net margin of -755.39%. InterCure's return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-755.39%	-64.75%	-57.62%
InterCure	N/A	N/A	N/A

9.1% of Lipocine shares are owned by institutional investors. Comparatively, 8.3% of InterCure shares are owned by institutional investors. 4.7% of Lipocine shares are owned by company insiders. Comparatively, 0.2% of InterCure shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lipocine has higher earnings, but lower revenue than InterCure.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	7.16	-$9.63M	-$1.79	N/A
InterCure	$78.47M	0.69	-$10.37M	N/A	N/A

Summary

Lipocine beats InterCure on 9 of the 14 factors compared between the two stocks.

Get Lipocine News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LPCN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LPCN vs. The Competition

Export

Metric	Lipocine	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.91M	$12.35B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-0.96	797.58	274.15	26.16
Price / Sales	9.03	939.82	635.98	112.53
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	0.66	10.71	11.21	6.34
Net Income	-$9.63M	$2.84B	$3.50B	$381.90M
7 Day Performance	-16.10%	-0.93%	-0.90%	-1.41%
1 Month Performance	-23.56%	-4.91%	-4.44%	-3.48%
1 Year Performance	-44.52%	-4.13%	6.96%	1.16%

Lipocine Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LPCN Lipocine	4.3033 of 5 stars	$1.72 -10.9%	$4.00 +132.6%	-45.4%	$15.91M	$1.57M	N/A	14	News Coverage Gap Down
HRTX Heron Therapeutics	1.9502 of 5 stars	$0.36 +13.5%	$2.00 +462.0%	-69.0%	$67.57M	$154.90M	N/A	128	News Coverage
ELOX Eloxx Pharmaceuticals	2.37 of 5 stars	$15.71 +2.6%	$38.33 +144.0%	N/A	$63.47M	$6.36M	N/A	7
ATHE Alterity Therapeutics	2.6626 of 5 stars	$3.49 -4.4%	$10.00 +186.5%	-30.7%	$63.27M	N/A	N/A	11	Gap Down
ZYBT Zhengye Biotechnology	0.8936 of 5 stars	$1.26 +5.0%	N/A	-36.4%	$59.71M	$116.36M	N/A	269	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LPCN) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lipocine (LPCN) Competitors

LPCN vs. HRTX, ELOX, ATHE, ZYBT, and INCR

How does Lipocine compare to Heron Therapeutics?

Summary

How does Lipocine compare to Eloxx Pharmaceuticals?

Summary

How does Lipocine compare to Alterity Therapeutics?

Summary

How does Lipocine compare to Zhengye Biotechnology?

Summary

How does Lipocine compare to InterCure?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN vs. The Competition

Lipocine Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lipocine (LPCN) Competitors

LPCN vs. HRTX, ELOX, ATHE, ZYBT, and INCR

How does Lipocine compare to Heron Therapeutics?

Do insiders and institutionals have more ownership in LPCN or HRTX?

Does the media favor LPCN or HRTX?

Which has more risk & volatility, LPCN or HRTX?

Do analysts recommend LPCN or HRTX?

Is LPCN or HRTX more profitable?

Which has preferable earnings and valuation, LPCN or HRTX?

Summary

How does Lipocine compare to Eloxx Pharmaceuticals?

Does the media prefer ELOX or LPCN?

Do institutionals & insiders believe in ELOX or LPCN?

Which has stronger valuation & earnings, ELOX or LPCN?

Which has more risk & volatility, ELOX or LPCN?

Do analysts prefer ELOX or LPCN?

Is ELOX or LPCN more profitable?

Summary

How does Lipocine compare to Alterity Therapeutics?

Which has preferable valuation & earnings, LPCN or ATHE?

Do analysts recommend LPCN or ATHE?

Which has more volatility and risk, LPCN or ATHE?

Do institutionals and insiders hold more shares of LPCN or ATHE?

Is LPCN or ATHE more profitable?

Does the media favor LPCN or ATHE?

Summary

How does Lipocine compare to Zhengye Biotechnology?

Does the media prefer LPCN or ZYBT?

Do analysts rate LPCN or ZYBT?

Which has preferable earnings and valuation, LPCN or ZYBT?

Which has more volatility & risk, LPCN or ZYBT?

Do insiders and institutionals believe in LPCN or ZYBT?

Is LPCN or ZYBT more profitable?

Summary

How does Lipocine compare to InterCure?

Does the media prefer LPCN or INCR?

Do analysts recommend LPCN or INCR?

Which has more volatility & risk, LPCN or INCR?

Is LPCN or INCR more profitable?

Do institutionals & insiders have more ownership in LPCN or INCR?

Which has preferable earnings and valuation, LPCN or INCR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LPCN vs. The Competition

Lipocine Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools